REG - Allergy Therapeutics - G306 Grass Phase III trial meets primary endpoint

Allergy TherapeuticsAnnouncement

14/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231114:nRSN3057Ta&default-theme=true

RNS Number : 3057T  Allergy Therapeutics PLC  14 November 2023

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

G306 pivotal Phase III trial to evaluate efficacy and safety of Grass MATA MPL
meets primary endpoint

 

-     Study demonstrated a highly statistically significant reduction in
Combined Symptom & Medication Score (CSMS) (p≤0.0024) achieved in active
treatment group compared to placebo

 

-     Analysis of primary outcome and secondary endpoints including
quality of life and biomarkers to be announced once full analysis of the data
has been completed

 

14 November 2023 Allergy Therapeutics plc (AIM: AGY), the integrated
commercial biotechnology company specialising in allergy vaccines, today
announces interim top line results from its pivotal G306 Phase III trial of
Grass MATA MPL, the Group's short-course subcutaneous allergen-specific
immunotherapy (SCIT) candidate that aims to address the cause of symptoms of
allergic rhinoconjunctivitis due to grass pollen.

 

The adaptive G306 study design, endorsed by regulators, allowed an interim
analysis to determine whether a 2nd cohort would be required. The trial met
its primary endpoint demonstrating statistically significant superiority of
Grass MATA MPL compared to placebo (p ≤0.0024, one-sided) in the CSMS during
the peak pollen season, and the study was stopped for success. Top line
analysis is expected to be available in mid-December. This will include
treatment effect data and secondary endpoint analysis.

 

The G306 trial was a multi-centre, randomised, parallel group, double-blind,
placebo-controlled clinical trial to evaluate the efficacy of Grass MATA MPL
27600 SU in subjects with grass pollen induced seasonal allergic rhinitis
and/or rhinoconjunctivitis based on symptoms and medications. The trial was
conducted in the US and Europe at 89 sites.

 

Manuel Llobet, CEO at Allergy Therapeutics, stated: "The completion of the
G306 study is an important milestone in our efforts to register this
innovative treatment for the benefit of the millions of patients affected by
grass allergies. I would like to thank our trial investigators, the team at
Allergy Therapeutics and, most importantly, the patients, for their
contributions. This result builds upon the statistical significance also seen
in the earlier G309(1) field study and, subject to full top line analysis, we
look forward to commencing discussions with relevant regulatory authorities to
continue our journey to bring this important product to market."

 

Preparation for a clinical trial application for the Group's G308 paediatric
study is currently underway to meet the previously communicated requirements
of the German regulatory framework (Therapy Allergen Ordinance) as well as the
approved Paediatric Investigation Plan (PIP).

 

This announcement contains inside information for the purposes of Article 7 of
Regulatory (EU) No596/2014.

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0) 20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

About Allergic Rhinitis

Allergic rhinitis and/or rhinoconjunctivitis is a type I allergic disease to
common aeroallergens such as pollen, mould spores and house dust mite residue.
Seasonal allergic rhinitis is most commonly caused by allergy to pollen from
tree, grasses or weeds, while perennial allergic rhinitis is most commonly
associated with allergy to dust mite residue, mould spores or animal dander(2)

 

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy
product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

 

Grass MATA MPL contains an extract of 13 grass pollens modified with
glutaraldehyde (allergoid) to reduce the reactivity with immunoglobulin E
(IgE) antibodies without a reduction in other important immunological
properties, such as T-cell reactivity. The allergoid is adsorbed to L-tyrosine
as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is
included as an adjuvant to increase the immunogenic effect of the
immunotherapy and to enhance the switch from an allergen specific helper
T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response.

 

More information about the Phase III G306 Grass MATA MPL trial can be found on
ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home) under the identifier
NCT05540717 (https://clinicaltrials.gov/ct2/show/NCT05540717) .

 

References

1.   Short-course subcutaneous treatment with PQ Grass strongly improves
symptom and medication scores in grass allergy. de Kam PJ, Zielen S, Bernstein
JA, Berger U, Berger M, Cuevas M, Cypcar D, Fuhr-Horst A, Greisner WA, Jandl
M, Laßmann S, Worm M, Matz J, Sher E, Smith C, Steven GC, Mösges R, Shamji
MH, DuBuske L, Borghese F, Oluwayi K, Zwingers T, Seybold M, Armfield O, Heath
MD, Hewings SJ, Kramer MF, Skinner MA. Allergy. 2023 Oct;78(10):2756-2766.

2.   van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW,
Durham SR, et al. Consensus statement on the treatment of allergic rhinitis.
European Academy of Allergology and Clinical Immunology. Allergy. 2000;
55(2):116-34.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAFFDFLEDFAA